Purpura, Thrombocytopenic, Idiopathic Clinical Trial
Official title:
Prolonging the Response by Low-dose Rituximab Maintenance Therapy in Immune Thrombocytopenia: a Randomized Placebo-controlled Trial - the PROLONG Trial
This study is a two phase study that aims to evaluate if low-dose Rituximab maintenance therapy may prolong the the effect of Rituximab in immune thrombocytopenia.
This is a multi-center, international, randomized, two-phase study: First phase (induction phase) is open-label, hypothesis-generating, involving 1:1 randomization into: rituximab (group 1) or rituximab plus dexamethasone (group 2) to determine if the response to rituximab can be improved by the addition of dexamethasone. Second Phase (maintenance phase) is the main part of the study, involving 1:1 double-blind randomization into low dose rituximab or placebo to determine if the response achieved in the first phase can be prolonged by administrating maintenance treatment with low dose rituximab. Primary objective: To determine if maintenance therapy with low-dose rituximab is superior to placebo in prolonging responses among ITP patients who achieved an initial response with rituximab. Secondary objectives: 1. To explore if the initial overall response rate, at week 24, can be improved by at least 10% by adding dexamethasone to rituximab (induction phase). 2. To assess the safety of study treatment, especially infectious episodes (induction & maintenance phases). 3. To assess bleeding complications during the study (induction & maintenance phases). 4. To assess the use of rescue medications and other platelet-elevating therapies during the study (induction & maintenance phases). 5. To determine rate of Complete Response (CR) during induction phase and sustained CR during maintenance phase (induction & maintenance phases). 6. To determine the duration of overall response and CR (induction & maintenance phases). 7. To assess health-related quality of life and fatigue (induction & maintenance phases). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01356511 -
High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)
|
Phase 4 | |
| Completed |
NCT00540423 -
Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
|
Phase 3 | |
| Completed |
NCT00372892 -
Pilot Study of Rituximab for the Treatment of Acute Immune Thrombocytopenic Purpura (ITP)
|
Phase 2 | |
| Not yet recruiting |
NCT03252457 -
Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP
|
Phase 3 | |
| Completed |
NCT00151840 -
Efficacy and Safety of IVIG-L in ITP Patients
|
Phase 3 | |
| Recruiting |
NCT05438875 -
The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9
|
Phase 3 | |
| Completed |
NCT02281370 -
Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects
|
Phase 1 | |
| Terminated |
NCT00547066 -
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
|
Phase 1/Phase 2 | |
| Completed |
NCT00370331 -
RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag
|
Phase 3 | |
| Completed |
NCT00828750 -
Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
|
Phase 3 | |
| Completed |
NCT00487968 -
Eltrombopag Taste Testing in Healthy Adult Volunteers
|
Phase 1 | |
| Withdrawn |
NCT01317966 -
Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
|
N/A | |
| Not yet recruiting |
NCT03443570 -
Rituximab Combining Bortezomib Versus Rituximab in Management of ITP
|
Phase 3 | |
| Completed |
NCT01610180 -
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
|
Phase 2 | |
| Completed |
NCT02201290 -
A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
|
Phase 3 | |
| Completed |
NCT00220727 -
Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP
|
Phase 2 | |
| Completed |
NCT02334813 -
Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia
|
Phase 3 | |
| Completed |
NCT02891109 -
Regulatory B Cells and Chronic Immune Thrombocytopenia
|
N/A | |
| Completed |
NCT00706342 -
Pilot Study of be Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
|
Phase 2 | |
| Completed |
NCT03258866 -
The Study of Different Dose Rituximab in the Treatment of ITP
|
Phase 4 |